Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 25/2/2021
SIETES contiene 93212 citas

 1 a 17 de 17 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Golomb BA, Verden A, Messner AK, Koslik HJ, Hoffman KB. Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA's adverse event reporting system. Drug Saf 2018;41:abril. [Ref.ID 102565]
2. Cita con resumen
Ham AC, van Dijk SC, Swart KMA, Enneman AW, van der Zwaluw NL, Brouwer-Brolsma EM, van Schoor NM, Zillikens MC, Lips P, de Groot LCPGM, Hofman A, Witkamp RF, Uitterlinden AG, Stricker BH, van der Velde N. Beta-blocker use and fall risk in older individuals: Original results from two studies with meta-analysis. Br J Clin Pharmacol 2017;83:2292-302. [Ref.ID 102082]
3. Cita con resumen
Quinn KL, Macdonald EM, Mamdani MM, Diong C, Juurlink DN, for the Canadian Drug Safety and Effectiveness Research Network (CDSERN). Lipophilic statins and the risk of intracranial hemorrhage following ischemic stroke: a population-based study. Drug Saf 2017;40:887-93. [Ref.ID 102077]
4. Cita con resumen
Lee YC, Lin CH, Wu RM, Lin MS, Lin JW, Chang CH, Lai MS. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology 2013;81:410-6. [Ref.ID 95841]
5. Cita con resumen
Farmer JA. Learning from the cerivastatin experience. Lancet 2001;358:1383-4. [Ref.ID 58775]
6. Cita con resumen
Cheymol G. Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet 2000;39:215-31. [Ref.ID 52614]
7.Tiene citas relacionadas Cita con resumen
Fagerberg B, on behalf of the MERIT-HF Interventional Executive Committee. Pharmacological treatment of systolic heart failure. Author's reply. Lancet 1999;354:1471-2. [Ref.ID 47455]
8.Tiene citas relacionadas Cita con resumen
Liedholm H, Linné A B, Merlo J. Pharmacological treatment of systolic heart failure. Lancet 1999;354:1471. [Ref.ID 47454]
Waller D. Opioid analgesics: differences and similarities. Prescr J 1993;33:227-31. [Ref.ID 21056]
10. Cita con resumen
Anónimo. Beta-blockers and lipophilicity. Lancet 1987;1:900. [Ref.ID 9967]
11.Tiene citas relacionadas
Boisse NR, Okamoto M. Physical dependence to barbital compared to pentobarbital. IV. Influence of elimination kinetics. J Pharmacol Exp Ther 1978;204:526-40. [Ref.ID 5299]
Compston JE, Thompson RPH. Intestinal absorption of 25-hydroxyvitamin D and osteomalacia in primary biliary cirrhosis. Lancet 1977;1:721-4. [Ref.ID 2371]
13. Cita con resumen
Hogben CAM, Tocco DJ, Brodie BB, Schanker LS. On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther 1959;125:275-82. [Ref.ID 140]
14. Cita con resumen
Brodie BB, Kurz H, Schanker LS. The importance of dissociation constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid. J Pharmacol Exp Ther 1960;130:20-5. [Ref.ID 137]
15. Cita con resumen
Goldstein A, Aronow L. The durations of action of thiopental and pentobarbital. J Pharmacol Exp Ther 1960;128:1-6. [Ref.ID 136]
16. Cita con resumen
Hume AS, Bush MT, Remick J, Douglas BH. Comparison of gastric absorption of thiopental and pentobarbital in rat, dog, and man. Arch Int Pharmacodyn Ther 1968;171:122-7. [Ref.ID 118]
17. Cita con resumen
Kakemi K, Arita T, Hori R, Konishi R. Absorption and excretion of drugs. XXX. Absorption of barbituric acid derivatives from rat stomach. Chem Pharm Bull (Tokyo) 1967;15:1534-9. [Ref.ID 107]
Seleccionar todas
 1 a 17 de 17